Veritas In Silico has formed a strategic partnership with Takeda Pharmaceutical to jointly develop innovative mRNA-targeted low-molecular-weight therapeutics for genetic diseases.
Information on the Target
Veritas In Silico (VIS), headquartered in Shinagawa, Tokyo, and led by President Shingo Nakamura, has entered into a collaborative research and licensing agreement with Takeda Pharmaceutical Company Limited. This partnership aims to develop innovative low-molecular-weight pharmaceuticals targeting mRNA for the treatment of various genetic diseases.
Since its establishment, VIS has focused on mRNA-targeted drug discovery and aims to create a society where patients with any disease do not lose hope due to the unavailability of treatments. Their integrated drug discovery platform, ibVIS®, incorporates rule-based AI software, and since 2018, the company has engaged in joint drug discovery research with pharmaceutical firms to develop mRNA-targeted low-molecular-weight drugs for conditions such as cancer, neurological disorders, and infectious diseases.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
The pharmaceutical industry in Japan is one of the most advanced in the world, characterized by rigorous research and innovation processes. With a strong emphasis on biotechnology and genetics, the country has a rep
Similar Deals
武田薬品工業株式会社
invested in
株式会社Veritas In Silico
in 2024
in a Joint Venture deal